Global Radiopharmaceuticals Market Size is valued at USD 6.2 Billion in 2024 and is predicted to reach USD 19.6 Billion by the year 2034 at a 12.7% CAGR during the forecast period for 2025-2034.
Radiopharmaceuticals are medications that incorporate radioactive isotopes. These chemicals are utilized in the field of nuclear medicine for diagnostic and therapeutic applications. They produce detectable radiation that may be captured in images, enabling healthcare workers to visually examine and evaluate the performance of organs, tissues, and physiological processes in the body. In addition to traditional cancer therapies, the oncologist may consider utilizing radiopharmaceuticals, which employ a blend of radioactive particles and drugs to selectively target and eradicate cancer cells. Radiopharmaceuticals are a specific category of radioactive compounds used in modern medicine. The drugs that contain radionuclides are as follows. Most radiopharmaceuticals employ a radioactive nuclide or radionuclide in combination with a drug or biologically active substance to assess the distribution and localization within the body.
Furthermore, the rising range of radiopharmaceuticals is finding its way into clinical practice, providing doctors with more specific data about the features of various tumour forms. Many cancers are responding to radionuclides as a soothing and curative therapeutic option.
However, the market growth is hampered by the strict regulatory criteria for the safety and health of the radiopharmaceuticals market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high radiopharmaceuticals because radiopharmaceuticals are costly to create and execute because the market might not be growing quickly, several possible roadblocks could stop the sector from reaching its maximum potential. In all their manifestations, government regulations are thus deemed a barrier to product introduction. Every nation has several regulatory bodies, and every country has its own distinct set of rules. Strict regulatory and product approval processes are expected to slow the growth of the global radiopharmaceutical market.
The catastrophic COVID-19 pandemic impacts have shocked the world's healthcare institutions and crippled their operations. Consequently, hospitals have ramped up testing to save lives and contain the infection. The COVID-19 pandemic has created significant financial difficulties, and governments worldwide have been forced to reduce spending.
The Radiopharmaceuticals Market is segmented based on radioisotope, technology type, indication, source, type, and end user. Based on Radioisotope, the market is segmented into technetium 99, fluorine 18, iodine 131, leutetium 177, yttrium 90, gallium 67, gallium 68, rubidium 82, iodine 123, iodine 125, indium 111, other isotopes. Based on the Indication, the market is divided into oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and other indications. Based on the Source, the market is divided into cyclotrons, nuclear reactors, and other sources. Based on the type, the segment is divided into diagnostic and therapeutic. Based on the end Use, the market is divided into hospitals, medical imaging centres, and cancer research institutes.
Based on radioisotope, the market is segmented into technetium 99, fluorine 18, iodine 131, leutetium 177, yttrium 90, gallium 67, gallium 68, rubidium 82, iodine 123, iodine 125, indium 111, other isotopes. Among these, the technetium-99m segment is expected to have the highest growth rate during the forecast period. Technetium-99m (Tc-99m) dominates the radiopharmaceuticals market primarily because of its ideal characteristics for diagnostic imaging and the well-established global infrastructure for its production and distribution. Tc-99m has been used since the 1960s, and infrastructure for its production, transport, and usage is highly developed and regulated.
Based on the Indication, the market is divided into oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and other indications. Among these segments, the oncology segment dominates the market. Rising incidence of cancers such as prostate, breast, lung, and neuroendocrine tumours. Cancer is one of the prominent causes of death worldwide, driving high demand for advanced diagnostic and therapeutic solutions. Oncology dominates the radiopharmaceuticals market due to its high disease burden, use of both diagnostic and therapeutic agents, and the rise of personalized medicine through theranostic approaches.
North America leads the radiopharmaceuticals market due to the widespread availability of PET/SPECT scanners and nuclear medicine facilities, along with the high adoption of advanced diagnostics and targeted therapies in hospitals and imaging centres. The region has a large patient pool requiring radiopharmaceutical-based diagnostics and therapies, driven by a significant burden of cancer and other chronic diseases. Additionally, there is a strong demand for personalized medicine and early cancer detection, supported by a robust healthcare system and technological advancements.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 6.2 Billion |
|
Revenue Forecast In 2034 |
USD 19.6 Billion |
|
Growth Rate CAGR |
CAGR of 12.7 % from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By radioisotope, technology type, indication, source, type, and end user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novartis AG, Curium, Bayer AG, Telix Pharmaceuticals, Lantheus Holdings, Inc., GE Healthcare, Cardinal Health, Jubilant Pharmova, ITM Isotope Technologies, Eli Lilly (via POINT Biopharma), AstraZeneca (via Fusion Pharmaceuticals), PharmaLogic Holdings, Life Molecular Imaging, Bracco Imaging, Siemens Healthineers, Eckert & Ziegler, Advanced Accelerator Applications (AAA), NorthStar Medical Radioisotopes, Nusano Inc., Progenics Pharmaceuticals |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceuticals Market Snapshot
Chapter 4. Global Radiopharmaceuticals Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on Radiopharmaceuticals Market Industry Trends
4.10. Global Radiopharmaceuticals Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Radiopharmaceuticals Market Segmentation 1: By Radioisotope, Estimates & Trend Analysis
5.1. Market Share by Radioisotope, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Radioisotope:
5.2.1. Technetium 99
5.2.2. Fluorine 18
5.2.3. Iodine 131
5.2.4. Leutetium 177
5.2.5. Yttrium 90
5.2.6. Gallium 67
5.2.7. Gallium 68
5.2.8. Rubidium 82
5.2.9. Iodine 123
5.2.10. Iodine 125
5.2.11. Indium 111
5.2.12. Other Isotopes
Chapter 6. Radiopharmaceuticals Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Oncology
6.2.2. Cardiology
6.2.3. Gastroenterology
6.2.4. Neuroendocrinology
6.2.5. Neurology
6.2.6. Nephrology
6.2.7. Other Indications
Chapter 7. Radiopharmaceuticals Market Segmentation 3: By End-User Industry, Estimates & Trend Analysis
7.1. Market Share by End-User Industry, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User Industry:
7.2.1. Hospitals
7.2.2. Medical Imaging Centers
7.2.3. Cancer Research Institute
Chapter 8. Offline Radiopharmaceuticals Market Segmentation 4: By Source, Estimates & Trend Analysis
8.1. Market Share by Source, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Source:
8.2.1. Cyclotrons
8.2.2. Nuclear Reactors
8.2.3. Other Sources
Chapter 9. Radiopharmaceuticals Market Segmentation 5: By Type, Estimates & Trend Analysis
9.1. Market Share by Type, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
9.2.1. Diagnostic
9.2.2. Therapeutic
Chapter 10. Radiopharmaceuticals Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Radiopharmaceuticals Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.2.3. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.2.4. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.2.5. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
10.2.6. North America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.3. Europe
10.3.1. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.3.3. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.3.4. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.3.5. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
10.3.6. Europe Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.4.3. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.4.4. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts Source, 2021-2034
10.4.5. Asia Pacific Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.5. Latin America
10.5.1. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.5.3. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.5.4. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.5.5. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
10.5.6. Latin America Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Radioisotope, 2021-2034
10.6.3. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.6.4. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.6.5. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
10.6.6. Middle East & Africa Radiopharmaceuticals Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Novartis AG
11.2.1.1. Business Overview
11.2.1.2. Key Radioisotope/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Curium
11.2.3. Bayer AG
11.2.4. Telix Pharmaceuticals
11.2.5. Lantheus Holdings, Inc.
11.2.6. GE Healthcare
11.2.7. Cardinal Health
11.2.8. Jubilant Pharmova
11.2.9. ITM Isotope Technologies
11.2.10. Eli Lilly (via POINT Biopharma)
11.2.11. AstraZeneca (via Fusion Pharmaceuticals)
11.2.12. PharmaLogic Holdings
11.2.13. Life Molecular Imaging
11.2.14. Bracco Imaging
11.2.15. Siemens Healthineers
11.2.16. Eckert & Ziegler
11.2.17. Advanced Accelerator Applications (AAA)
11.2.18. NorthStar Medical Radioisotopes
11.2.19. Nusano Inc.
11.2.20. Progenics Pharmaceuticals
Global Radiopharmaceuticals Market - By Radioisotope
Global Radiopharmaceuticals Market – By Source
Global Radiopharmaceuticals Market – By Type
Global Radiopharmaceuticals Market – By End User
Radiopharmaceuticals Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
